Biglycan enhances gastric cancer invasion by activating FAK signaling pathway

Lei Hu; Yan-tao Duan; Jian-fang Li; Li-ping Su; Min Yan; Zheng-gang Zhu; Bing-ya Liu; Qiu-meng Yang

doi:10.18632/oncotarget.1871

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Biglycan enhances gastric cancer invasion by activating FAK signaling pathway

Lei Hu, Yan-tao Duan, Jian-fang Li, Li-ping Su, Min Yan, Zheng-gang Zhu, Bing-ya Liu _ and Qiu-meng Yang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2014; 5:1885-1896. https://doi.org/10.18632/oncotarget.1871

Metrics: PDF 5331 views | HTML 3813 views | ?

Abstract

Lei Hu1,*, Yan-tao Duan1,*, Jian-fang Li1, Li-ping Su1, Min Yan1, Zheng-gang Zhu1, Bing-ya Liu1, Qiu-meng Yang1

1 Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China.

* These authors contributed equally to this work

Correspondence:

Bing-ya Liu, email:

Qiu-meng Yang, email:

Keywords: BGN, Gastric cancer, Metastasis, FAK

Received: January 1, 2014 Accepted: March 24, 2014 Published: March 26, 2014

Abstract

Biglycan (BGN) is an important member of small leucine-rich proteoglycans family, and has been implicated in oncogenesis and development of various human cancer types. Here we report that BGN promotes tumor invasion and metastasis of gastric cancer both in vitro and in vivo. BGN expression is significantly higher in gastric cancer tissues and associated with lymph node metastasis, depth of tumor invasion and TNM stage. BGN enhances gastric cancer cell wound healing, migration and invasion ability as well as the tube formation ability of endothelial cells in vitro. Animal experiments results in vivo are consistent with outcomes in vitro. BGN induces increased phosphorylation of FAK (Tyr576/577, Tyr925 and Tyr397) and Paxillin. These results indicate that BGN is upregulated, and plays an oncogenic role, in gastric cancer metastasis by activating the FAK signaling pathway.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1871

Publication Alerts

Research Papers:

Biglycan enhances gastric cancer invasion by activating FAK signaling pathway

Abstract